Kyowa Kirin (4151) Collaboration summary

Opening remarks and agenda

• Conference call introduced to discuss the global strategic collaboration between two companies for the development and commercialization of ziftomenib, with a Q&A session following the main remarks.

Objectives of the partnership

• Collaboration aims to accelerate global development and commercialization of ziftomenib, maximizing benefits for patients and shareholders.

• Focus on developing blockbuster opportunities in hematologic malignancies, solid tumors, diabetes, and rare diseases through a license agreement for ziftomenib.

• Partnership provides resources to fund the AML program through to commercialization in critical frontline combinations.

Partner introductions and roles

• One partner retains program leadership in the U.S. and key strategic rights, ensuring flexibility and optionality, while the other leads regulatory and commercialization efforts outside the U.S., leveraging global presence and expertise.

• Key executives involved include Chief Strategy Officer Yasuo Fujii, Chief Medical Officer Takeyoshi Yamashita, Head of Finance Motohiko Kawaguchi, and Chief International Business Officer Abdul Mullick.

• Both partners have a history of successful collaborations and a strong focus on hematology/oncology.